Current and emerging therapies for nonalcoholic fatty liver disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter will discuss state-of-the-art of various therapies for nonalcoholic fatty liver disease (NAFLD). As only patients with nonalcoholic steatohepatitis (NASH) are generally at risk for progressing to end-stage liver disease and hepatocellular carcinoma, liver-directed therapies to improve or reverse NASH are directed at this population. The most tested options with some efficacy are weight loss, vitamin E, and pioglitazone. In the morbidly obese patients with NASH, bariatric surgery is effective at improving or resolving the liver injury, but its safety is unknown in NASH patients with cirrhosis. Liver transplantation offers excellent patient and graft survival for NASH patients with cirrhosis and liver failure or early stage hepatocellular carcinoma. Existing literature does not currently support the use of many previously tested agents for NAFLD and NASH such as metformin, long-chain polyunsaturated fatty acids, or ursodeoxycholic acid. A number of emerging therapeutics agents in different stages of testing are reviewed as well. Recent data from a large randomized trial of obeticholic acid in patients with NASH is encouraging but requires validation and long-term safety data. Finally, addressing the metabolic and cardiac comorbidities is an important element in managing all patients with NAFLD. In this setting, statins can be safely used when indicated to treat dyslipidemia.

Original languageEnglish (US)
Title of host publicationAlcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside
PublisherSpringer International Publishing
Pages313-337
Number of pages25
ISBN (Electronic)9783319205380
ISBN (Print)9783319205373
DOIs
StatePublished - Jan 1 2015

Fingerprint

Therapeutics
pioglitazone
Hepatocellular Carcinoma
Fibrosis
Non-alcoholic Fatty Liver Disease
Art Therapy
Safety
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ursodeoxycholic Acid
End Stage Liver Disease
Bariatric Surgery
Metformin
Liver
Liver Failure
Graft Survival
Dyslipidemias
Unsaturated Fatty Acids
Vitamin E
Liver Transplantation
Comorbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gawrieh, S., & Chalasani, N. (2015). Current and emerging therapies for nonalcoholic fatty liver disease. In Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside (pp. 313-337). Springer International Publishing. https://doi.org/10.1007/978-3-319-20538-0_16

Current and emerging therapies for nonalcoholic fatty liver disease. / Gawrieh, Samer; Chalasani, Naga.

Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside. Springer International Publishing, 2015. p. 313-337.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gawrieh, S & Chalasani, N 2015, Current and emerging therapies for nonalcoholic fatty liver disease. in Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside. Springer International Publishing, pp. 313-337. https://doi.org/10.1007/978-3-319-20538-0_16
Gawrieh S, Chalasani N. Current and emerging therapies for nonalcoholic fatty liver disease. In Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside. Springer International Publishing. 2015. p. 313-337 https://doi.org/10.1007/978-3-319-20538-0_16
Gawrieh, Samer ; Chalasani, Naga. / Current and emerging therapies for nonalcoholic fatty liver disease. Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside. Springer International Publishing, 2015. pp. 313-337
@inbook{f6af6ff456244762bf4cad8610b4c7ad,
title = "Current and emerging therapies for nonalcoholic fatty liver disease",
abstract = "This chapter will discuss state-of-the-art of various therapies for nonalcoholic fatty liver disease (NAFLD). As only patients with nonalcoholic steatohepatitis (NASH) are generally at risk for progressing to end-stage liver disease and hepatocellular carcinoma, liver-directed therapies to improve or reverse NASH are directed at this population. The most tested options with some efficacy are weight loss, vitamin E, and pioglitazone. In the morbidly obese patients with NASH, bariatric surgery is effective at improving or resolving the liver injury, but its safety is unknown in NASH patients with cirrhosis. Liver transplantation offers excellent patient and graft survival for NASH patients with cirrhosis and liver failure or early stage hepatocellular carcinoma. Existing literature does not currently support the use of many previously tested agents for NAFLD and NASH such as metformin, long-chain polyunsaturated fatty acids, or ursodeoxycholic acid. A number of emerging therapeutics agents in different stages of testing are reviewed as well. Recent data from a large randomized trial of obeticholic acid in patients with NASH is encouraging but requires validation and long-term safety data. Finally, addressing the metabolic and cardiac comorbidities is an important element in managing all patients with NAFLD. In this setting, statins can be safely used when indicated to treat dyslipidemia.",
author = "Samer Gawrieh and Naga Chalasani",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-20538-0_16",
language = "English (US)",
isbn = "9783319205373",
pages = "313--337",
booktitle = "Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Current and emerging therapies for nonalcoholic fatty liver disease

AU - Gawrieh, Samer

AU - Chalasani, Naga

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This chapter will discuss state-of-the-art of various therapies for nonalcoholic fatty liver disease (NAFLD). As only patients with nonalcoholic steatohepatitis (NASH) are generally at risk for progressing to end-stage liver disease and hepatocellular carcinoma, liver-directed therapies to improve or reverse NASH are directed at this population. The most tested options with some efficacy are weight loss, vitamin E, and pioglitazone. In the morbidly obese patients with NASH, bariatric surgery is effective at improving or resolving the liver injury, but its safety is unknown in NASH patients with cirrhosis. Liver transplantation offers excellent patient and graft survival for NASH patients with cirrhosis and liver failure or early stage hepatocellular carcinoma. Existing literature does not currently support the use of many previously tested agents for NAFLD and NASH such as metformin, long-chain polyunsaturated fatty acids, or ursodeoxycholic acid. A number of emerging therapeutics agents in different stages of testing are reviewed as well. Recent data from a large randomized trial of obeticholic acid in patients with NASH is encouraging but requires validation and long-term safety data. Finally, addressing the metabolic and cardiac comorbidities is an important element in managing all patients with NAFLD. In this setting, statins can be safely used when indicated to treat dyslipidemia.

AB - This chapter will discuss state-of-the-art of various therapies for nonalcoholic fatty liver disease (NAFLD). As only patients with nonalcoholic steatohepatitis (NASH) are generally at risk for progressing to end-stage liver disease and hepatocellular carcinoma, liver-directed therapies to improve or reverse NASH are directed at this population. The most tested options with some efficacy are weight loss, vitamin E, and pioglitazone. In the morbidly obese patients with NASH, bariatric surgery is effective at improving or resolving the liver injury, but its safety is unknown in NASH patients with cirrhosis. Liver transplantation offers excellent patient and graft survival for NASH patients with cirrhosis and liver failure or early stage hepatocellular carcinoma. Existing literature does not currently support the use of many previously tested agents for NAFLD and NASH such as metformin, long-chain polyunsaturated fatty acids, or ursodeoxycholic acid. A number of emerging therapeutics agents in different stages of testing are reviewed as well. Recent data from a large randomized trial of obeticholic acid in patients with NASH is encouraging but requires validation and long-term safety data. Finally, addressing the metabolic and cardiac comorbidities is an important element in managing all patients with NAFLD. In this setting, statins can be safely used when indicated to treat dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=85016773565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016773565&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-20538-0_16

DO - 10.1007/978-3-319-20538-0_16

M3 - Chapter

AN - SCOPUS:85016773565

SN - 9783319205373

SP - 313

EP - 337

BT - Alcoholic and Non-Alcoholic Fatty Liver Disease: Bench to Bedside

PB - Springer International Publishing

ER -